Inhaled Antibiotic Therapy in Chronic Respiratory Diseases.
Inhaled Antibiotic Therapy in Chronic Respiratory Diseases.
复制标题
DOI：
10.3390/ijms18051062
复制
发表时间：
2017-05-16
影响因子：
5.6
通讯作者：
Restrepo MI
中科院分区：
文献类型：
--
作者：
Maselli DJ;Keyt H;Restrepo MI
慢性呼吸道疾病患者的管理受到难以治疗的感染的影响，已成为临床实践中的一个挑战。囊性纤维化(CF)和非囊性纤维支气管扩张症等疾病需要广泛的治疗策略来应对多重耐药病原体，包括铜绿假单胞菌、耐甲氧西林金黄色葡萄球菌、伯克霍尔德氏菌和非结核分枝杆菌(NTM)。这些挑战促使科学家通过肺部系统使用吸入、雾化或雾化抗生素来传递抗菌剂。随后的研究进展集中在开发能够达到高组织浓度的抗生素制剂，能够减少患有慢性呼吸道疾病的宿主中难以治疗的生物的细菌负荷。在这篇综述中，我们重点介绍了通过呼吸系统通过吸入、雾化或雾化给药的抗生素治疗的证据，特别是在慢性呼吸系统疾病患者中，包括CF、非CF支气管扩张和NTM。然而，需要进一步的研究来解决吸入型抗生素在管理慢性呼吸道疾病患者难于治疗的感染方面的潜在好处、作用机制和应用。
The management of patients with chronic respiratory diseases affected by difficult to treat infections has become a challenge in clinical practice. Conditions such as cystic fibrosis (CF) and non-CF bronchiectasis require extensive treatment strategies to deal with multidrug resistant pathogens that include Pseudomonas aeruginosa, Methicillin-resistant Staphylococcus aureus, Burkholderia species and non-tuberculous Mycobacteria (NTM). These challenges prompted scientists to deliver antimicrobial agents through the pulmonary system by using inhaled, aerosolized or nebulized antibiotics. Subsequent research advances focused on the development of antibiotic agents able to achieve high tissue concentrations capable of reducing the bacterial load of difficult-to-treat organisms in hosts with chronic respiratory conditions. In this review, we focus on the evidence regarding the use of antibiotic therapies administered through the respiratory system via inhalation, nebulization or aerosolization, specifically in patients with chronic respiratory diseases that include CF, non-CF bronchiectasis and NTM. However, further research is required to address the potential benefits, mechanisms of action and applications of inhaled antibiotics for the management of difficult-to-treat infections in patients with chronic respiratory diseases.